The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts

Pediatrics

Volumn 135, Issue 5, 2015, Pages e1131-e1140

  Smith, Leah M ^a   Strumpf, Erin C ^a,b   Kaufman, Jay S ^a   Lofters, Aisha ^c   Schwandt, Michael ^d   Lévesque, Linda E ^e,f  

^a and Occupational Health ^*  (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CANADA; CHILD; CHILD HEALTH CARE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; PROGRAM IMPACT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; UTERINE CERVIX DYSPLASIA; VACCINATION; AGE; ANUS DISEASES; COHORT ANALYSIS; CONDYLOMATA ACUMINATA; GENITAL DISEASES, FEMALE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA;

AGE FACTORS; ANUS DISEASES; CHILD; COHORT STUDIES; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; UTERINE CERVICAL DYSPLASIA;

EID: 84929485667     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2961     Document Type: Article

References (45)

1. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(suppl 1):S1-S15
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; (24 suppl 3):S3/11-25
3. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278-285
4. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995; 33(8):2058-2063
5. Parry J. Vaccinating against cervical cancer. Bull World Health Organ. 2007; 85(2):89-90
6. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: A systematic review of randomized controlled trials. CMAJ. 2007;177(5):469-479
7. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: A systematic review & meta-analysis. BMC Infect Dis. 2011;11:13
8. Haas M, Ashton T, Blum K, et al. Drugs, sex, money and power: an HPV vaccine case study. Health Policy. 2009;92(2-3): 288-295
9. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine. 2012;30(suppl 5):F139-F148
10. National Advisory Committee on Immunization (NACI). Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2007;33(ACS-2):1-31
11. Rahman M, Laz TH, Berenson AB. Geographic variation in human papillomavirus vaccination uptake among young adult women in the United States during 2008-2010. Vaccine. 2013; 31(47):5495-5499
12. Colucci R, Hryniuk W, Savage C. HPV Vaccination Programs in Canada. Are we hitting the mark? In: The Cancer Advocacy Coalition of Canada, Report Card, 2008. Available at: www. canceradvocacy.ca/reportcard/2008/HPV-20Vaccination-20Programs-20in -20Canada.pdf. Accessed March 18, 2015
13. Ogilvie G, Anderson M, Marra F, et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med. 2010;7(5): e1000270
14. Dorell C, Yankey D, Jeyarajah J, et al. Delay and refusal of human papillomavirus vaccine for girls, national immunization survey-teen, 2010. Clin Pediatr (Phila). 2014;53(3):261-269
15. Perkins RB, Clark JA, Apte G, et al. Missed opportunities for HPV vaccination in adolescent girls: A qualitative study. Pediatrics. 2014; 134(3). Available at: www.pediatrics.org/cgi/content/full/134/3/e666
16. Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2012; 42(1):44-52
17. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study. BMC Med. 2013;11:227
18. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014; 106(3):djt460
19. Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol. 2014;32(5):438-443
20. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348: g1458
21. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: A Swedish national cohort study. J Natl Cancer Inst. 2013; 105(7):469-474
22. Ministry of Health and Long-Term Care. Ontario's HPV vaccination program. 2013. Available at: www.health.gov.on.ca/en/ms/hpv/. Accessed March 13, 2014
23. Institute for Clinical Evaluative Sciences. Data discovery, better health. Available at: www.ices.on.ca/Data-and-Privacy/ICES-data/Types-of-Data. Accessed March 1, 2014
24. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22): 2634-2643
25. Lipscombe LL, Lévesque L, Gruneir A, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med. 2009;169(14): 1282-1289
26. Kwong JC, Tanuseputro P, Zagorski B, Moineddin R, Chan KJ. Impact of varicella vaccination on health care outcomes in Ontario, Canada: effect of a publicly funded program? Vaccine. 2008;26(47): 6006-6012
27. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination in adults: A population-based study. Arch Intern Med. 2006;166(20): 2217-2221
28. Smith LM, Brassard P, Kwong JC, Deeks SL, Ellis AK, Lévesque LE. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health. 2011;11:645
29. Smith LM, Kaufman JS, Strumpf EC, Levesque LE. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. CMAJ. 2015;187(2):E74-E81
30. Lévesque LE, Smith LM, Perry AG, et al. The Ontario Grade 8 HPV Vaccine Cohort Study: A Feasibility and Validity Evaluation. In: Ontario Vaccine Sciences Symposium. Toronto, ON; November 24, 2011
31. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol. 1992;136(2):121-135
32. Chen RT, Davis RL, Rhodes PH. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Sussex, UK: John Wiley & Sons, Ltd; 2005:455-485
33. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35(2):337-344
34. Nelson JC, Jackson ML, Weiss NS, Jackson LA. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol. 2009;62(7): 687-694
35. Hahn J, Todd P, Van der Klaauw W. Identification and estimation of treatment effects with a regressiondiscontinuity design. Econometrica. 2001; 69:201-209
36. Imbens GW, Lemieux T. Regression discontinuity designs: A guide to practice. J Econom. 2008;142:615-635
37. Cook TD. ''Waiting for Life to Arrive'': A history of the regression-discontinuity design in psychology, statistics and economics. J Econom. 2007;142:636-654
38. Kadiyala S, Strumpf EC. How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the U.S. Guideline Screening Initiation Ages (July 1, 2011). Available at: http://dx.doi.org/10.2139/ssrn.1893793. Accessed March 18, 2015
39. Meyer BD, Wherry LR. Saving Teens: Using a Policy Discontinuity to Estimate the Effects of Medicaid Eligibility. Cambridge Massachusetts: The National Bureau of Economic Research; 2012: 1-74. Available at: www.nber.org/papers/w18309. Accessed March 18, 2015
40. O'Keeffe AG, Geneletti S, Baio G, Sharples LD, Nazareth I, Petersen I. Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. BMJ. 2014;349:g5293
41. Bor J, Moscoe E, Mutevedzi P, Newell ML, Bärnighausen T. Regression discontinuity designs in epidemiology: causal inference without randomized trials. Epidemiology. 2014;25(5): 729-737
42. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317(7168):1309-1312
43. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA. 2013;309(17): 1793-1802
44. Smith LM, Lévesque LE, Nasr M, Perry AG. Validity of the Immunization Record Information System (IRIS) database for epidemiologic studies of the human papillomavirus (HPV) vaccine. Canadian Journal of Clinical Pharmacoepidemiology. 2010;17: e90-e127
45. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;(24 suppl 3): S3/42-51